Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

[1]  H. Frederiksen,et al.  Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications , 2020, Cancers.

[2]  N. Kucine.  Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults , 2020, Current Hematologic Malignancy Reports.

[3]  M. Griesshammer,et al.  Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. , 2019, Blood.

[4]  M. Griesshammer,et al.  Second cancers in MPN: Survival analysis from an international study , 2019, American journal of hematology.

[5]  Junshik Hong,et al.  Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. , 2019, Blood advances.

[6]  M. Deininger,et al.  Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need? , 2019, HemaSphere.

[7]  J. Radich,et al.  Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms , 2019, Hematological oncology.

[8]  N. Lavi,et al.  Characteristics and outcomes of young adults with Philadelphia‐negative myeloproliferative neoplasms , 2019, European journal of haematology.

[9]  M. Griesshammer,et al.  Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study , 2019, Leukemia.

[10]  N. Siritanaratkul,et al.  A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms , 2019, BMC Cancer.

[11]  C. Harrison,et al.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review , 2019, Haematologica.

[12]  T. Barbui,et al.  Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management , 2018, American journal of hematology.

[13]  T. Biss,et al.  Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations. , 2019, Journal of pediatric hematology/oncology.

[14]  A. Tefferi,et al.  Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger , 2018, American journal of hematology.

[15]  P. Kamath,et al.  Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases , 2018, American journal of hematology.

[16]  T. Barbui,et al.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.

[17]  P. Dickman,et al.  Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients , 2018, Leukemia.

[18]  Z. Estrov,et al.  Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms , 2017, Annals of Hematology.

[19]  D. Xia,et al.  Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms , 2016, American journal of hematology.

[20]  S. Bang,et al.  Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea , 2016, Journal of Korean medical science.

[21]  T. Barbui,et al.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both , 2016, Leukemia.

[22]  Hyewon Lee,et al.  Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012 , 2015, Blood research.

[23]  I. Hofmann.  Myeloproliferative neoplasms in children , 2015, Journal of Hematopathology.

[24]  R. Skoda,et al.  Mutational profile of childhood myeloproliferative neoplasms , 2015, Leukemia.

[25]  J. W. Kim,et al.  Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. , 2015, Thrombosis research.

[26]  Ayalew Tefferi,et al.  Myeloproliferative Neoplasms A Contemporary Review , 2015 .

[27]  Murim Choi,et al.  JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms , 2015, Haematologica.

[28]  L. Kim,et al.  A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples , 2014, Epidemiology and health.

[29]  M. Cazzola,et al.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.

[30]  Mike Clarke,et al.  How common are myeloproliferative neoplasms? A systematic review and meta‐analysis , 2014, American journal of hematology.

[31]  Hongwei Wang,et al.  Epidemiology of myeloproliferative neoplasms in the United States , 2014, Leukemia & lymphoma.

[32]  F. Bertucci,et al.  Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms , 2012, Genes, chromosomes & cancer.

[33]  L. Larocca,et al.  Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. , 2012, Blood.

[34]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[35]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[36]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[37]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[38]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[39]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[40]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.